Ganymed Robotics develops a proprietary technology platform combining computer vision and mechatronics to create robotic assistance for orthopedic surgery, with its first application a surgical assistant for total knee arthroplasty (TKA). The company is advancing a next-generation surgical robot and says the funding will accelerate that development. It launched a clinical trial in September 2021 to validate its algorithms and collect in vivo data, with 50 patients enrolled and 36 more to come. Ganymed holds a U.S. patent and has five additional patents pending. The company plans to deploy its technology across other orthopedic indications and aims to become a global category leader in surgical orthopedics by the end of the decade. Recent management moves include appointing Michel Vernizeau as VP of R&D and attracting direct investment from two international orthopedic surgeons. Ganymed Robotics is a Parisian computer-vision software and surgical-robotics company developing a surgical robotic assistant for knee arthroplasty (TKA). The company raised an additional €15 million as a Series B extension, bringing the total Series B to €36 million after an initial €21 million announced in July. €14 million of the extension was provided by the European Innovation Council (EIC) Fund via the EIC Accelerator Program and Cap Horn Invest (a member of the Anaxago Group), while Bpifrance provided €1 million in debt financing. The new capital is intended to complete development of Ganymed’s TKA robotic assistant, accelerate regulatory and market-access activities, and help the company expand beyond TKA with a diversified product lineup. CEO and co-founder Sophie Cahen said the financing, following an oversubscribed Series B first close, places the company in a solid position amid a worldwide financing crunch. Ganymed aims to bring its patented technology to market with the goal of becoming the standard of care for joint replacement. Ganymed Robotics develops a computer-vision and mechatronics platform to assist orthopedic surgeons, with its first application a co-manipulated robotic assistant for total knee arthroplasty (TKA). The company has validated proprietary algorithms and collected in vivo data via a 100-patient observational study and completed functional prototype tests. It has initiated industrialization of its first TKA device through strategic partnerships and secured a robust patent portfolio. Ganymed plans to finalize industrial development, complete regulatory work, and prepare a commercial launch while expanding in France and the United States. The company intends to diversify its innovation pipeline and progressively deploy the technology to additional orthopedic indications. Ganymed is based in Paris, was founded in 2018, and currently employs 25 people.

Total raised

$40M

Funding rounds

4

Latest round

Grant

Latest activity

Mar 2024